Abstract PS4-08-06: Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Prospective Study (AMENDER)
Authors
X. Sun
C. Li
K. Zhao
H. Mo
G. Wang
L. Zhang
H. Ge
F. Ma
Y. Zhang
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
National Cancer Center (US)
Burning Rock Biotech (China) (CN)
Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Abstract PS4-08-06: Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Prospective Study (AMENDER)
X. Sun, C. Li, K. Zhao, H. Mo et al.
Journal
Clinical Cancer Research
Topics
Cancer Genomics and Diagnostics
article
Abstract PS4-08-06: Optimizing Postoperative Adjuvant Therapy for Early-Stage Breast Cancer by Combining Dynamic ctDNA MRD Monitoring with Clinical Risk Stratification: An Open-label, Multicenter, Prospective Study (AMENDER)
X. Sun, C. Li, K. Zhao, H. Mo, G. Wang, L. Zhang, H. Ge, F. Ma, Y. Zhang
article en
Abstract
No abstract available for this paper.
Publication Tag
Clinical Cancer ResearchVol. 32(4_Supplement)
Institutions
Chinese Academy of Medical Sciences & Peking Union Medical College (CN), National Cancer Center (US), Burning Rock Biotech (China) (CN), Cancer Hospital of Huanxing Chaoyang District Beijing (CN)